BMO Capital Markets reiterated their hold rating on shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) in a research report sent to investors on Friday morning. BMO Capital Markets currently has a $39.00 target price on the biotechnology company’s stock.
A number of other equities analysts have also commented on the stock. Royal Bank Of Canada started coverage on shares of Five Prime Therapeutics in a report on Thursday, September 14th. They issued an outperform rating and a $41.00 price target on the stock. ValuEngine raised shares of Five Prime Therapeutics from a strong sell rating to a sell rating in a report on Friday, June 2nd. Jefferies Group LLC reissued a buy rating and issued a $55.00 price target on shares of Five Prime Therapeutics in a report on Thursday, June 8th. Finally, BidaskClub lowered shares of Five Prime Therapeutics from a sell rating to a strong sell rating in a report on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. Five Prime Therapeutics currently has an average rating of Hold and a consensus target price of $54.86.
Shares of Five Prime Therapeutics (NASDAQ FPRX) traded up 0.28% during mid-day trading on Friday, reaching $35.34. 290,761 shares of the company’s stock were exchanged. The firm’s market cap is $988.99 million. The company has a 50 day moving average price of $31.18 and a 200 day moving average price of $32.04. Five Prime Therapeutics has a 52-week low of $25.97 and a 52-week high of $60.98.
Five Prime Therapeutics (NASDAQ:FPRX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.43). The firm had revenue of $7.80 million for the quarter, compared to the consensus estimate of $8.32 million. Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The business’s revenue was down 16.1% on a year-over-year basis. During the same period last year, the company posted ($0.49) EPS. Analysts forecast that Five Prime Therapeutics will post ($5.16) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/09/23/five-prime-therapeutics-inc-fprx-receives-hold-rating-from-bmo-capital-markets.html.
Several large investors have recently modified their holdings of FPRX. Nationwide Fund Advisors grew its holdings in shares of Five Prime Therapeutics by 3.1% during the 1st quarter. Nationwide Fund Advisors now owns 59,400 shares of the biotechnology company’s stock valued at $2,147,000 after purchasing an additional 1,771 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Five Prime Therapeutics by 19.1% during the 1st quarter. Wells Fargo & Company MN now owns 185,266 shares of the biotechnology company’s stock valued at $6,697,000 after purchasing an additional 29,701 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Five Prime Therapeutics by 7.0% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,030 shares of the biotechnology company’s stock valued at $724,000 after purchasing an additional 1,302 shares during the last quarter. Virginia Retirement Systems ET AL grew its holdings in shares of Five Prime Therapeutics by 50.9% during the 1st quarter. Virginia Retirement Systems ET AL now owns 40,300 shares of the biotechnology company’s stock valued at $1,457,000 after purchasing an additional 13,600 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Five Prime Therapeutics during the 1st quarter valued at $593,000. 84.05% of the stock is currently owned by hedge funds and other institutional investors.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.